Maturitas. 2011 Feb;68(2):103-5. doi: 10.1016/j.maturitas.2010.10.009. Epub 2010 Nov 19.
At the 2010 meeting of the European Society for Medical Oncology (ESMO), a landmark development in prostate cancer therapy was unveiled. In a phase III study, the CYP17 inhibitor abiraterone yielded a survival advantage over placebo in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed despite prior docetaxel therapy. The data for abiraterone follow the publication of successful phase III studies earlier this year supporting two mechanistically distinct agents-namely, the novel taxane cabazitaxel and the autologous dendritic cell vaccine sipuleucel-T. A challenge that lies ahead for the scientific community is to discern the appropriate positioning of abiraterone in an increasingly crowded therapeutic landscape. Several ongoing trials are examining the agent in earlier settings (i.e., a phase III in mCRPC pre-docetaxel, and smaller studies in combination with radiation therapy or as neoadjuvant pre-surgery for localized disease). Herein, several potential strategies for abiraterone are presented to clarify the clinical utilization of this agent in the future.
在 2010 年欧洲肿瘤内科学会（ESMO）会议上，前列腺癌治疗领域出现了一项具有里程碑意义的进展。在一项 III 期研究中，CYP17 抑制剂阿比特龙在先前接受多西他赛治疗后进展的转移性去势抵抗性前列腺癌（mCRPC）患者中，与安慰剂相比显示出生存优势。阿比特龙的数据紧随今年早些时候成功发表的两项支持两种机制不同药物的 III 期研究之后，这两种药物分别是新型紫杉烷 cabazitaxel 和自体树突状细胞疫苗 sipuleucel-T。科学界面临的一个挑战是，在日益拥挤的治疗领域中，确定阿比特龙的适当定位。几项正在进行的试验正在早期阶段（即 mCRPC 预先使用 docetaxel 的 III 期试验，以及与放射治疗联合或作为局部疾病术前新辅助治疗的较小规模研究）中研究该药物。本文提出了几种阿比特龙的潜在策略，以阐明未来该药物的临床应用。
